Contineum Therapeutics, Inc. Class A (CTNM) AI Stock Analysis

• Market Cap: $518.18M
• Dividend Yield: N/A
• Average Volume (3M): 170.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: N/A
• EPS Growth: -100.71%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 32,673,534
• 10 Day Avg. Volume: 105,448
• 30 Day Avg. Volume: 170,880
• PEG Ratio: 11.51
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.70
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.70K
• Enterprise Value/Ebitda: -6.52
• 1Y Price Target: $20.80
• Price Target Upside: 55.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -2.2
• Revenue Forecast (FY): $2.83M

• Rating: 50 Neutral
• Price Target: $14.00 ▲(4.71% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is held back primarily by weak financial performance (no recurring revenue, widening losses, and rising cash burn), partially offset by a stronger balance sheet and liquidity runway. Technical signals are mixed but not bearish, while valuation is difficult to anchor due to negative earnings and no dividend. Corporate updates support long-term execution potential but introduce dilution risk via the expanded ATM.

Positive Factors

Strong liquidity / multi-year runway

A $262.9M cash position and management guidance that resources fund operations through mid-2029 provides durable financial flexibility. This multi-year runway supports completion of key trials, reduces immediate financing pressure, and allows disciplined capital allocation toward lead programs.

Clinical progress — Phase 2 initiation

First-patient dosing in the global Phase 2 PROPEL-IPF study for PIPE-791 is a structural de-risking milestone. Advancing into Phase 2 demonstrates execution capacity, advances the regulatory timeline, and, if successful, would create a credible path to future revenues and partner interest.

Partnerships and external validation

Active collaborations, including J&J-led studies, provide validation, share development expense, and expand clinical expertise. These partnerships diversify program risk, enhance technical capabilities, and improve resource efficiency across the pipeline over the medium term.

Negative Factors

No recurring revenue

The absence of recurring revenues leaves the company dependent on successful clinical outcomes and financing to create sustainable cash flows. This structural revenue gap increases execution and funding risk until a commercial product is achieved.

Widening losses and rising cash burn

Materially higher operating outflows and widened EBIT losses reflect a persistent cash burn profile. Growing negative free cash flow necessitates further financing, constrains optionality, and forces prioritization across programs, increasing dilution risk for long-term investors.

Dilution risk from equity programs

An expanded $100M ATM and recent sizable equity raise, together with inducement equity awards, provide capital but embed ongoing dilution risk. Repeated share issuance to fund development can erode per-share returns and complicate long-term investor economics.

Contineum Therapeutics, Inc. Class A Business Overview & Revenue Model

Company Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

How the Company Makes Money

Contineum Therapeutics, Inc. generates revenue through a combination of product sales, licensing agreements, and strategic collaborations. The company commercializes its proprietary therapies once they receive regulatory approval and actively engages in partnerships with other pharmaceutical companies to co-develop and co-market its drug candidates. Additionally, Contineum Therapeutics may receive milestone payments and royalties from licensing its technology and products to partners. The company's revenue model is also supported by government grants and funding from research institutions that contribute to its research and development efforts.

Contineum Therapeutics, Inc. Class A Financial Statement Overview

Summary

Financial profile is pressured by $0 revenue in 2024–2025, widening operating losses (EBIT -$68.1M in 2025), and worsening cash burn (operating cash flow -$55.3M in 2025). The key offset is a materially stronger balance sheet with higher equity ($261.0M) and modest debt ($8.3M), providing funding flexibility despite negative ROE.

Income Statement

Earnings quality and visibility are weak: revenue was $0 in 2024 and 2025 after a one-off $50.0M in 2023, and profitability swung from a $22.7M profit in 2023 to sizable losses in 2024 (-$42.3M) and 2025 (-$60.0M). Losses have also widened year over year (EBIT fell to -$68.1M in 2025 from -$50.9M in 2024), consistent with a biotech still in heavy investment mode. Strength: the 2023 result shows the model can produce meaningful profit when revenue is present, but the lack of recurring revenue and rising loss profile drives the low score.

Balance Sheet

Balance sheet strength improved materially: stockholders’ equity rose to $261.0M in 2025 from $198.1M in 2024, while total debt remains modest at $8.3M (low leverage, ~0.03 debt-to-equity). This provides financial flexibility to fund operations. Key weakness is ongoing value erosion from losses, reflected in negative return on equity (about -23% in 2025). Also notable: 2023 showed highly stressed capitalization (negative equity and very high effective leverage), highlighting historical volatility even though the more recent position is stronger.

Cash Flow

Cash burn is significant and worsening: operating cash flow was -$55.3M in 2025 versus -$32.8M in 2024, and free cash flow was similarly negative (-$55.5M in 2025). While 2023 generated positive operating cash flow ($19.3M) and free cash flow ($18.9M), the business reverted to heavy outflows thereafter. A relative positive is that cash flow tracks reported losses closely (free cash flow roughly in line with net income in 2024–2025), suggesting losses are not being masked by large non-cash distortions—however, the absolute burn level remains the dominant risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	50.00M	0.00	0.00
Gross Profit	-323.00K	-258.00K	50.00M	-329.00K	0.00
EBITDA	-68.06M	-42.00M	23.57M	-23.54M	-28.34M
Net Income	-59.98M	-42.26M	22.72M	-24.25M	-29.00M
Balance Sheet
Total Assets	276.64M	212.85M	130.39M	50.64M	70.52M
Cash, Cash Equivalents and Short-Term Investments	262.90M	204.76M	125.19M	47.24M	69.00M
Total Debt	8.25M	6.26M	193.19M	5.85M	4.91M
Total Liabilities	15.65M	14.78M	198.32M	11.37M	8.93M
Stockholders Equity	260.99M	198.07M	-67.94M	39.27M	61.59M
Cash Flow
Free Cash Flow	-55.54M	-33.36M	18.93M	-20.24M	-26.43M
Operating Cash Flow	-55.31M	-32.84M	19.35M	-20.12M	-26.27M
Investing Cash Flow	-3.71M	-69.74M	-65.57M	22.30M	-64.97M
Financing Cash Flow	112.69M	109.00M	56.18M	-1.24M	79.84M

Contineum Therapeutics, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.37
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTNM, the sentiment is Neutral. The current price of 13.37 is below the 20-day moving average (MA) of 14.71, below the 50-day MA of 13.56, and above the 200-day MA of 10.09, indicating a neutral trend. The MACD of -0.17 indicates Positive momentum. The RSI at 44.07 is Neutral, neither overbought nor oversold. The STOCH value of 20.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTNM.

Contineum Therapeutics, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPR	61 Neutral	$1.66B	-11.68	-90.96%	―	-52.08%	-69.35%
IMRX	56 Neutral	$320.68M	-5.17	-43.33%	―	―	9.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTNM	50 Neutral	$518.18M	-5.28	-30.40%	―	―	-100.71%
DRTS	49 Neutral	$638.07M	-8.74	-57.29%	―	―	-22.82%
TVRD	46 Neutral	$36.49M	-16.53	-135.79%	―	-53.67%	86.75%
ENGN	46 Neutral	$484.33M	5.39	-5.15%	―	―	-52.86%

Contineum Therapeutics, Inc. Class A Corporate Events

Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress

Contineum Therapeutics amended its existing at-the-market equity program with Leerink Partners on March 5, 2026, raising the total capacity for Class A common stock issuance to $100 million, excluding amounts already sold, while committing not to sell shares under the facility until after a lock-up expires on March 11, 2026. The same day, the company reported fourth-quarter 2025 results, highlighting a $262.9 million cash position expected to fund operations through mid-2029, initiation of patient dosing in its global Phase 2 PROPEL-IPF trial of PIPE-791 in idiopathic pulmonary fibrosis, progress in chronic pain and depression studies with partners including Johnson & Johnson, and a modest year-over-year increase in quarterly net loss to $15.2 million despite disciplined spending on its expanding clinical pipeline.

The company also outlined that PROPEL-IPF, a 26-week, randomized, double-blind, placebo-controlled Phase 2 trial, will evaluate the efficacy, safety and tolerability of once-daily oral PIPE-791 in about 324 patients with idiopathic pulmonary fibrosis. In parallel, Contineum is advancing an exploratory Phase 1b chronic pain trial of PIPE-791, with topline data expected in the second quarter of 2026, while Johnson & Johnson continues a Phase 2 Moonlight-1 study of PIPE-307 in major depressive disorder, underscoring Contineum’s strategy to prioritize its lead IPF program while leveraging partnerships to broaden its NI&I pipeline.

The most recent analyst rating on (CTNM) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.

Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan

On January 23, 2026, Contineum Therapeutics, Inc.’s board approved a new 2026 Employment Inducement Equity Incentive Plan, modeled largely on its 2024 Equity Incentive Plan but limited to non-incentive stock options and awards granted only to individuals eligible under Nasdaq rules. Adopted without stockholder approval under Nasdaq Rule 5635(c)(4), the plan initially reserves 750,000 shares of Class A common stock and is designed to grant equity awards solely to new or returning employees as a material inducement to commence employment, underscoring the company’s use of stock-based incentives to attract and retain talent in a competitive market for specialized biopharmaceutical professionals.

The most recent analyst rating on (CTNM) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.

Contineum Therapeutics Submits Phase 2 Trial for PIPE-791

On December 8, 2025, Contineum Therapeutics, Inc. Class A announced the submission of its global Phase 2 clinical trial details for PIPE-791, aimed at treating idiopathic pulmonary fibrosis (IPF), to the ClinicalTrials.gov Protocol Registration and Results System. The trial, which is expected to enroll approximately 324 subjects globally, will evaluate the safety, tolerability, and efficacy of PIPE-791 over a 26-week period. The company plans to complete the trial by June 2028, with the trial design informed by previous regulatory engagement and Phase 1 clinical trials. This initiative highlights the company’s commitment to advancing treatment options for IPF, although it faces substantial risks and uncertainties related to clinical drug development, regulatory approvals, and market competition.

The most recent analyst rating on (CTNM) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.